News you can use: health & drug safety updates
January 13, 2016
Several prescription drugs are currently approved by the U.S. Food and Drug Administration (FDA) to treat people who have been diagnosed with Alzheimer’s disease. Treating the symptoms of Alzheimer’s can provide patients with comfort, dignity, and independence for a longer period of time and can encourage and assist their caregivers as well. It is important to understand that none of these medications stops the disease itself.
January 6, 2016
The U.S. Food and Drug Administration announced today it approved 21 new orphan drugs to treat rare diseases in 2015, nearly half (47 percent) of all novel new drugs approved for the year. This is the second consecutive year in which the FDA approved more orphan drugs for rare diseases than any previous year in FDA history, according to John K. Jenkins, M.D., Director, Office of New Drugs, Center for Drug Evaluation and Research at FDA. “The remarkable number of orphan drugs approved by FDA in 2015 underscores the progress we are making in
January 4, 2016
Prescription opioid pain relievers, such as oxycodone and hydrocodone, contribute to more overdose deaths than any other opioid type, according to new data from the Centers for Disease Control and Prevention (CDC). Overdose deaths related to such prescription opioids increased by 9% in 2014, accounting for 813 more deaths than in 2013, indicates a CDC press release. Misuse and abuse of prescription opioid pain relievers and use of heroin are major factors contributing to the sharp rise in overdose deaths. Dependence upon or abuse of prescription opioids in the
January 1, 2016
NCPIE serves as co-editor for a monthly column in Pharmacy Today (American Pharmacists Association) The column is entitled “One-to-One” and is intended to help develop pharmacists’ medication communication and counseling skills to promote safe and appropriate medicine use.